Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release Third Quarter 2026 Results on November 3, 202613.10.2026 23:15:00 EEST | Press release
IFF (NYSE: IFF) today announced that it will release its third quarter 2026 earnings results following the market close on Tuesday, November 3, 2026. The management team will host a live webcast on Wednesday, November 4, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, and health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire
Industry Leaders Formally Launch SCMP OCP Workstream for Open, Secure AI Infrastructure Management and Control13.10.2026 20:15:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, and AMI, a Lattice company, today announced SCMP (Secure Control and Management Plane), a new Open Compute Project workstream. Announced during a joint keynote at the 2026 OCP Global Summit, SCMP is an open, vendor-neutral architecture for secure control, boot, and management of data center infrastructure. It gives data center operators more confidence that complex AI systems will work as expected across vendors and platforms, with less integration risk and more freedom of choice. SCMP defines how a control authority establishes and maintains trust from silicon root of trust through rack and pod, building on existing OCP initiatives and industry standards. “As AI infrastructure scales toward autonomous operation, the management and control plane becomes the foundation of trust. That foundation should be open and verifiable, and SCMP gives the industry a common architecture to achieve it, from
Saudi Fund for Development Announces Progress on Pristina–Mitrovica Highway Project in Kosovo13.10.2026 16:36:00 EEST | Press release
The Saudi Fund for Development (SFD) today joined the Government of Kosovo to inaugurate the Pristina–Mitrovica Highway, marking SFD’s first completed project in Kosovo and an important milestone in the partnership between both sides. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013433726/en/ SFD CEO and Kosovar's minsters sideline meeting (Photo: AETOSWire) His Excellency Sultan bin Abdulrahman Al-Marshad, Chief Executive Officer of the Saudi Fund for Development, inaugurated the upgraded highway section by cutting the ribbon at the newly completed road. He subsequently held a sideline meetings with His Excellency Hekuran Murati, Minister of Finance, His Excellency Dimal Basha Minister of Infrastructure and Transport, and His Excellency Arben Vitia, Minister of Health, to discuss the development projects and the continued SFD- Kosovo partnership. The project upgrades a 9.87 km section of the Prishtina–Mitrovica Highway
KAST Selects Kiln’s Claire Wells as Chief Legal Officer13.10.2026 16:30:00 EEST | Press release
KAST, the global money app, announced today that Claire Wells has joined the company as Chief Legal Officer. Wells will lead KAST’s global legal operations, and the company’s compliance, regulatory, fundraising and licensing initiatives are under her remit. Wells is a proven legal and compliance leader with deep experience building and scaling legal, regulatory and policy functions across fintech, payments and digital assets. She has navigated complex, multi-jurisdictional environments, all while delivering growth. “I’m thrilled that Claire has joined the KAST team as our new Chief Legal Officer,” said KAST Founder & CEO Raagulan Pathy. “Claire is joining us at a truly pivotal time for the company as we enter our next phase of growth. We are continuing to expand our product set rapidly, and her strategic leadership will be instrumental in scaling our operations into a truly global powerhouse.” This is a significant hire for KAST. To meet fast-growing global demand, the company now has
Ohana Development Announces Erling Haaland as a Proud Homeowner at Manchester City Yas Residences by Ohana, During Phase 2 Launch13.10.2026 16:00:00 EEST | Press release
Ohana Development has announced Erling Haaland as a proud homeowner at Manchester City Yas Residences by Ohana during the launch of the project’s second phase. Featuring two- and three-bedroom townhouses, duplex villas, and four- and five-bedroom villas, Phase 2 sales will commence on 19 October 2026. The event at Etihad Arena welcomed over 4,000 guests, including Pep Guardiola, who was announced as the project’s official brand ambassador. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013790618/en/ Manchester City Yas Residences by Ohana Launches Phase 2 (Photo: AETOSWire) Located along Yas Canal, adjacent to Yas Island, the development spans 1.67 million square metres and will feature more than 2,000 residences. The world’s first Manchester City-branded residential community has already broken ground, with phased delivery scheduled by 2029. In a video appearance by Manchester City star Erling Haaland, he announced that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom